TGap Ventures

TGap Ventures, LLC is a venture capital firm based in Kalamazoo, Michigan, founded in 2002. The firm specializes in early-stage investments, focusing on high-growth companies within various sectors, including software, life sciences, medical devices, healthcare services, telecommunications, internet infrastructure, specialty manufacturing, and plastics. TGap Ventures typically invests between $0.5 million and $1 million in companies seeking financing ranging from $1.5 million to $7 million. The firm prefers to co-invest and aims for financial exits or liquidity events exceeding $50 million. It also seeks to secure a board seat in its portfolio companies and generally holds its investments for five to seven years.

Jack Ahrens II

Owner and Founding General Partner

Peter Farner

General Partner

13 past transactions

HistoSonics

Series B in 2017
HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

NeoChord

Series C in 2015
NeoChord, Inc. is a medical technology company based in St. Louis Park, Minnesota, that focuses on developing innovative devices for the treatment of degenerative mitral valve disease (DMR). Founded in 2007, the company has created the NeoChord Artificial Chordae Delivery System, a disposable device designed for minimally invasive mitral valve repair. This system allows surgeons to replace damaged chordae through a small incision of 2 to 3 inches between the ribs, enabling the procedure to be performed on a beating heart. This approach contrasts sharply with traditional methods, which typically involve larger incisions and stopping the heart, thus reducing recovery time and associated complications. NeoChord's technology aims to improve surgical outcomes for patients suffering from severe mitral regurgitation, which can lead to serious conditions such as atrial fibrillation and congestive heart failure.

Revenew

Venture Round in 2014
Revenew International, LLC is a provider of cost recovery and cost containment services, specializing in helping clients ensure compliance with commercial terms, recover lost funds, and enhance operational practices. Founded in 1999 and headquartered in Houston, Texas, with additional offices across various U.S. cities and in Canada, the company offers a comprehensive suite of services. These include contract compliance reviews, supplier payment audits, and performance improvement strategies aimed at optimizing the procurement-to-payment cycle for commercial clients, particularly within Fortune 500 companies in sectors like energy and power. Revenew's focus on enhancing supplier relationships and streamlining operations allows clients to manage costs effectively while mitigating risks.

Inspire Medical Systems

Series E in 2014
Inspire Medical Systems, Inc. is a medical technology company dedicated to developing and commercializing minimally invasive solutions for patients suffering from obstructive sleep apnea (OSA). Founded in 2007 and headquartered in Golden Valley, Minnesota, the company specializes in innovative implantable neurostimulation technologies. Its primary product, the Inspire system, utilizes a proprietary Upper Airway Stimulation (UAS) therapy that provides a safe and effective treatment for moderate to severe OSA. This technology leverages established principles from cardiac pacing and neurostimulation to deliver mild hypoglossal nerve stimulation, which helps maintain an open airway by continuously monitoring the patient's breathing. Inspire Medical Systems operates primarily in the United States and Europe, generating most of its revenue from the U.S. market.

Revenew

Series B in 2013
Revenew International, LLC is a provider of cost recovery and cost containment services, specializing in helping clients ensure compliance with commercial terms, recover lost funds, and enhance operational practices. Founded in 1999 and headquartered in Houston, Texas, with additional offices across various U.S. cities and in Canada, the company offers a comprehensive suite of services. These include contract compliance reviews, supplier payment audits, and performance improvement strategies aimed at optimizing the procurement-to-payment cycle for commercial clients, particularly within Fortune 500 companies in sectors like energy and power. Revenew's focus on enhancing supplier relationships and streamlining operations allows clients to manage costs effectively while mitigating risks.

Inspire Medical Systems

Series C in 2012
Inspire Medical Systems, Inc. is a medical technology company dedicated to developing and commercializing minimally invasive solutions for patients suffering from obstructive sleep apnea (OSA). Founded in 2007 and headquartered in Golden Valley, Minnesota, the company specializes in innovative implantable neurostimulation technologies. Its primary product, the Inspire system, utilizes a proprietary Upper Airway Stimulation (UAS) therapy that provides a safe and effective treatment for moderate to severe OSA. This technology leverages established principles from cardiac pacing and neurostimulation to deliver mild hypoglossal nerve stimulation, which helps maintain an open airway by continuously monitoring the patient's breathing. Inspire Medical Systems operates primarily in the United States and Europe, generating most of its revenue from the U.S. market.

NeoChord

Series B in 2011
NeoChord, Inc. is a medical technology company based in St. Louis Park, Minnesota, that focuses on developing innovative devices for the treatment of degenerative mitral valve disease (DMR). Founded in 2007, the company has created the NeoChord Artificial Chordae Delivery System, a disposable device designed for minimally invasive mitral valve repair. This system allows surgeons to replace damaged chordae through a small incision of 2 to 3 inches between the ribs, enabling the procedure to be performed on a beating heart. This approach contrasts sharply with traditional methods, which typically involve larger incisions and stopping the heart, thus reducing recovery time and associated complications. NeoChord's technology aims to improve surgical outcomes for patients suffering from severe mitral regurgitation, which can lead to serious conditions such as atrial fibrillation and congestive heart failure.

Regenesis Biomedical

Series C in 2011
Regenesis Biomedical Inc. is a medical device company based in Scottsdale, Arizona, founded in 1996. The company specializes in the research, design, manufacture, and sale of noninvasive regenerative medicine products aimed at alleviating pain and restoring health. Its primary product, the Provant Therapy System, utilizes an electromagnetic field to reduce pain and swelling in skin and soft tissues following surgical procedures. The company serves a diverse clientele that includes healthcare facilities, acute and long-term care hospitals, skilled nursing facilities, rehabilitation centers, outpatient clinics, and home healthcare providers, all catering to patients under physician orders. Through its innovative approach, Regenesis Biomedical strives to enhance the quality of life for patients experiencing post-operative discomfort.

HistoSonics

Series A in 2010
HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

ValenTx

Series A in 2006
ValenTx, Inc. is a medical device company based in Maple Grove, Minnesota, established in 2002. It specializes in developing minimally invasive therapy solutions aimed at treating obesity and its related metabolic disorders, including type-2 diabetes and hypertension. One of its key innovations is an endoluminal bypass therapy that replicates the anatomical changes associated with the Roux-en-Y gastric bypass procedure using an adjustable, removable, and replaceable device. ValenTx's focus is on providing effective treatment options for individuals struggling with morbid obesity and related health issues.

Small Bone Innovations

Series B in 2005
Small Bone Innovations (SBi) is a medical device company specializing in the design, manufacture, and distribution of implants tailored for small bones and joints. Their product portfolio focuses on trauma and arthroplasty applications, catering specifically to the thumb, hand, wrist, elbow, foot, and ankle regions. SBi's offerings include basal joint arthritis treatments and implants designed to replace anatomic joint surfaces while preserving bones and minimizing disruption to collateral ligaments and soft tissues.

InStadium

Venture Round in 2005
InStadium is a live sports marketing network that connects brands with fans at over 425 professional and collegiate stadiums and arenas across the United States. The company specializes in in-venue advertising and promotional marketing services, providing brands with unique engagement opportunities during live sporting events. By leveraging a vast national venue network, InStadium enables year-round access to multiple markets, allowing clients to execute integrated media and promotional campaigns tailored to their marketing schedules. This approach allows brands to reach millions of engaged consumers at thousands of events each year, enhancing brand visibility and consumer interaction in a dynamic environment.

MinuteClinic

Series C in 2004
MinuteClinic is a provider of retail-based healthcare services that focuses on delivering affordable and convenient medical care both in-person and virtually. The clinic offers a variety of primary care services, including treatments for common health issues such as allergies, bladder infections, bronchitis, ear infections, pink eye, styes, sinus infections, strep throat, and swimmer's ear. By providing accessible healthcare solutions, MinuteClinic enables individuals to receive necessary medical attention at a low cost, making healthcare more accessible to a broader population.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.